All In Biotech

Drug Trial Radar · NCT00767000

Dose Range Finding Study of MK-0941 in Patients With Type 2 Diabetes Mellitus on Insulin (MK-0941-007 AM3 EXT1 AM1)(TERMINATED)

A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Range Finding Clinical Trial of MK0941 in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Insulin

Last checked: Nov 19, 2026Latest source record: Feb 19, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingRandomized with 813 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

813

Actual

Start

Oct 2008

Primary completion

Apr 2010

Study completion Jun 2010

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 6, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 21 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to test the effect of MK-0941 as add-on therapy for participants taking insulin for type 2 diabetes mellitus. The primary hypotheses of this study are that treatment with MK-0941 added to insulin will provide greater reduction in hemoglobin A1c (HbA1c) level than will placebo added to insulin at 14 weeks, and that MK-0941 will be well-tolerated at 1 or more doses that demonstrate efficacy.

Conditions

  • Diabetes Mellitus, Type 2

Interventions

  • MK-0941Drug

    MK-0941 tablets three times daily

  • Comparator: PlaceboDrug

    Matching placebo to MK-0941 three times daily

  • LantusBiological

    Lantus injection once daily

  • MetforminDrug

    Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study. The number of randomized participants who receive metformin will be capped at 70% of enrollment.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Hemoglobin A1c (HbA1c) LevelTime frame: Baseline and Weeks 14, 54, 106, and 158
  2. Percentage of Participants Who Experienced at Least One Adverse EventTime frame: Entire study including 54-week study and 104-week extension
  3. Percentage of Participants Who Discontinued Study Medication Due to an Adverse EventTime frame: Entire study including 54-week study and 104-week extension

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.